Logo

American Heart Association

  2
  0


Final ID: Su1043

Risk of the Post-Partum Period Among Women with Diagnosed and Treated Type 2 Long QT Syndrome (LQT2)

Abstract Body (Do not enter title and authors here): Background: Long QT syndrome (LQTS) is a potentially lethal cardiac channelopathy. Among women with LQT2, the post-partum period has been considered high risk for cardiac events. However, whether this risk persists after establishing their diagnosis and implementing their LQT2-directed treatment program remains to be determined.

Objective: To describe the management and outcomes of LQT2 women during the 9 months post-partum period.

Methods: A retrospective analysis of 1869 patients with LQTS treated and evaluated at a tertiary center specializing in Genetic Heart Disease from January 2000 to November 2023 was performed to identify women with diagnosed and treated LQT2 who had a pregnancy during follow-up. Data were abstracted for patient demographics, clinical characteristics, symptomatic status, and treatment plans before and after pregnancy.

Results: Overall, 30 pregnancies occurred in 22 women with LQT2. Their average QTc was 489 ± 34 ms with 7 patients (32%) having a resting QTc > 500 ms. Prior to their first post-partum period, 5/22 (23%) were symptomatic with 2 (9%) experiencing a LQT2-triggered sudden cardiac arrest (SCA). Before their post-partum period, their LQT2-directed therapy comprised preventative measures only in 7 (23%), drug therapy in 16 (53%), combination therapy in 7 (23%), and 10 women (43%) had an implantable cardioverter defibrillator (ICD). Pre-emptive treatment intensification was done for 24/30 post-partum periods. Only a single VF-terminating ICD therapy occurred in 1 (3%) of the 30 post-partum periods involving a 21-year-old with p.Lys610Asn-KCNH2 variant, QTc = 490 ms, and a pre-diagnosis presentation of seizures.

Conclusion: Although the post-partum period is regarded as a ‘high risk’ window of time for women with LQT2, the risk of a LQT2-triggered cardiac event after diagnosis and implementation of contemporary therapies is very low. This designation of “high risk” among correctly diagnosed and treated women is misleading and generates inappropriate and unnecessary anxiety.
  • Neves, Raquel  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Bains, Sahej  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Bos, Johan  ( Mayo Clinic College of Medicine , Rochester , Minnesota , United States )
  • Giudicessi, John  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Ackerman, Michael  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Author Disclosures:
    Raquel Neves: DO NOT have relevant financial relationships | Sahej Bains: DO NOT have relevant financial relationships | Johan Bos: DO NOT have relevant financial relationships | John Giudicessi: DO have relevant financial relationships ; Consultant:Avidity Biosciences:Active (exists now) ; Other (please indicate in the box next to the company name):Prolaio (equity/royalty sharing):Active (exists now) ; Research Funding (PI or named investigator):Tenaya Therapeutics:Active (exists now) | Michael Ackerman: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Royalties/Patent Beneficiary:Thryv Therapeutics:Active (exists now) ; Royalties/Patent Beneficiary:Pfizer:Past (completed) ; Royalties/Patent Beneficiary:ARMGO Pharma:Active (exists now) ; Royalties/Patent Beneficiary:Anumana:Active (exists now) ; Royalties/Patent Beneficiary:AliveCor:Active (exists now) ; Consultant:Tenaya Therapeutics:Active (exists now) ; Consultant:Solid Biosciences:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Consultant:Invitae:Active (exists now) ; Consultant:Illumina:Active (exists now) ; Consultant:Daiichi Sankyo:Past (completed) ; Consultant:Bristol Myers Squibb:Active (exists now) ; Consultant:Boston Scientific:Active (exists now) ; Consultant:BioMarin Pharmaceutical:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Biobank and Population Studies of Clinical Cardiovascular Genetics

Sunday, 11/17/2024 , 03:15PM - 04:15PM

Abstract Poster Session

More abstracts on this topic:
Antisense Oligonucleotide Treatment of Calmodulinopathy

Bortolin Raul, Yoshinaga Daisuke, Pavlaki Nikoleta, Cavazzoni Cecilia B., T. Sage Peter, D. Whitehill Robert, Abrams Dominic, Carreon Chrystalle, Putra Juan, Alexandrescu Sanda, Guo Shuai, Nawar Farina, Tsai Owen, Rubart Michael, Kubli Dieter, Mullick Adam, Bezzerides Vassilios, Pu William, Trembley Michael, Prondzynski Maksymilian, Sweat Mason, Wang Peizhe, Chaehyoung Park, Lu Fujian, Keating Erin

Aberrant MicroRNA Expression May Underlie Cardiac Dysfunction in a rat model of Preeclampsia

Vaka Ramana, Campbell Nathan, Edwards Kristin, Hoang Ngoc, Zheng Baoying, Lamarca Babbette

More abstracts from these authors:
The Risk of Cardiac Events Associated with Psychiatric Drugs in Patients with Long QT Syndrome.

Ferreira Felix Iuri, Karlinski Vizentin Vanessa, Neves Raquel, Bains Sahej, Bos Johan, Giudicessi John, Ackerman Michael

Common Misdiagnoses During the Workup of Inherited Channelopathies

Bains Sahej, Neves Raquel, Bos Johan, Giudicessi John, Ackerman Michael

You have to be authorized to contact abstract author. Please, Login
Not Available